GlassScriptPhysician profile
Lymay Kouai
NPI 1407214539
$3,795.87
in general payments reported to CMS, 2019-2025
30 companies · $16.66 in 2025
The $16.66 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,054 · 2022: $482 · 2023: $1,187 · 2024: $1,056 · 2025: $16.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.26 | 2021-2024 | |
| Emd Serono, INC. | $568.93 | 2022-2024 | Mavenclad |
| Ucb, INC. | $258.73 | 2021-2024 | Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $256.34 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $211.20 | 2021-2023 | Austedo |
| Amgen INC. | $210.59 | 2021-2023 | Aimovig |
| Jazz Pharmaceuticals INC. | $179.44 | 2021-2024 | |
| Harmony Biosciences LLC | $150.58 | 2022-2024 | Wakix |
| Biogen, INC. | $144.97 | 2021-2023 | Tysabri |
| Lilly USA, LLC | $116.88 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Pfizer INC. | $107.11 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $90.02 | 2021-2024 | Rytary |
| Alexion Pharmaceuticals, INC. | $78.21 | 2023 | Soliris, Ultomiris |
| Argenx US, INC. | $65.27 | 2024 | Vyvgart Hytrulo |
| Celgene Corporation | $65.23 | 2021-2023 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $63.64 | 2023-2024 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $55.24 | 2022 | |
| Sk Life Science, INC. | $51.19 | 2022-2024 | |
| Genentech USA, INC. | $50.99 | 2024 | Ocrevus, Enspryng |
| Mdd US Operations, LLC | $46.04 | 2021 | |
| Tg Therapeutics, INC. | $44.53 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $40.38 | 2024 | Lumryz |
| Eisai INC. | $39.87 | 2021-2023 | |
| Upsher-Smith Laboratories LLC | $36.73 | 2023 | |
| Neurelis, INC. | $34.91 | 2023 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $33.91 | 2021 | |
| Axsome Therapeutics, INC. | $32.39 | 2024 | Sunosi |
| Lundbeck LLC | $23.63 | 2023 | Vyepti |
| Arbor Pharmaceuticals, INC. | $18.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.98 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lymay Kouai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.